Martin R Jakobsen

Summary

Affiliation: Macfarlane Burnet Institute for Medical Research and Public Health
Country: Australia

Publications

  1. doi request reprint Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome
    Martin R Jakobsen
    Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark
    Clin Infect Dis 50:566-73. 2010
  2. pmc T Cells Detect Intracellular DNA but Fail to Induce Type I IFN Responses: Implications for Restriction of HIV Replication
    Randi K Berg
    Department of Infectious Diseases, Aarhus University Hospital Skejby, Aarhus, Denmark
    PLoS ONE 9:e84513. 2014
  3. doi request reprint Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient
    Martin R Jakobsen
    Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark
    Clin Infect Dis 46:e88-91. 2008

Collaborators

  • Lars Ostergaard
  • Paul R Gorry
  • Ole S Sogaard
  • Randi K Berg
  • Trine H Mogensen
  • Emil Kofod-Olsen
  • Stine H Rahbek
  • Louise B Jørgensen
  • Christian K Holm
  • Søren R Paludan
  • Jesper Melchjorsen
  • Carsten S Larsen
  • Martin Tolstrup
  • Anne Louise Hansen
  • David G Jensen

Detail Information

Publications3

  1. doi request reprint Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome
    Martin R Jakobsen
    Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark
    Clin Infect Dis 50:566-73. 2010
    ....
  2. pmc T Cells Detect Intracellular DNA but Fail to Induce Type I IFN Responses: Implications for Restriction of HIV Replication
    Randi K Berg
    Department of Infectious Diseases, Aarhus University Hospital Skejby, Aarhus, Denmark
    PLoS ONE 9:e84513. 2014
    ..This phenomenon could contribute to the high permissiveness of CD4+ T cells for HIV-1. ..
  3. doi request reprint Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient
    Martin R Jakobsen
    Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark
    Clin Infect Dis 46:e88-91. 2008
    ..After 26 weeks of entecavir therapy, the M184V mutation dominated the plasma viral population. Thus, entecavir should only be used for coinfected patients who simultaneously receive suppressive therapy against HIV infection...